Of these, PRIMA-1MET (p53-dependent reactivation of massive apoptosis) (also known as APR-246), is a pro-drug that generates active compound methylene quinuclidinone (MQ), which binds cysteine residues in the DNA-binding domain of mutant-p53, resulting in refolding into wild-type-p53 confirmation and subsequent restoration of tumor suppressor activity in a number of cancer models [19,20]. Here, TP53 is linked to neoplasm.